Immuno-Inflammatory Program

CombinatoRx currently has two clinical stage product candidates --
CRx-102 and CRx-139 -- targeting immuno-inflammatory diseases and multiple additional preclinical product candidates. Immuno-inflammatory diseases include rheumatoid arthritis, osteoarthritis, atopic dermatitis, psoriasis, inflammatory bowel disease, asthma, inflammatory ocular diseases, lupus, polymyalgia rheumatica, and multiple sclerosis.

CRx-102 and CRx-139

Of the clinical stage immuno-inflammatory product candidates that are advancing through or into clinical trials for the treatment of immuno-inflammatory diseases, CRx-102 and CRx-139 can be broadly defined as dissociated steroids. With these product candidates, we seek to selectively amplify the potent immuno-modulatory activity of steroids, with reduced side effects, which is also known as a dissociated steroid.

Steroids of the corticosteroid class are prescribed for the treatment of immuno-inflammatory diseases. The utility of these drugs, however, is limited by their substantial, dose-dependent adverse side effects. Each of our clinical stage selective steroid amplifier product candidates consists of a low-dose corticosteroid combined with a different second active ingredient which our prior clinical studies suggest enhances the low-dose steroid's anti-inflammatory and immuno-modulatory activities. This is without, we believe, a comparable increase in the steroid's adverse side effects. Preclinical investigations of CRx-102 and CRx-139 suggest that these drug candidates have different effects on important components of the immune system. As a result, each of our selective steroid amplifier product candidates may have a distinct clinical profile and potential utility in multiple or different immuno-inflammatory diseases.

Additional drug candidates for the treatment of immuno-inflammatory diseases are currently in preclinical development.